Furthermore, pirfenidone was suggested as a viable treatment option that protected against CYP-induced steroid-resistant allergic pneumonitis via M1 macrophage polarization suppression by modulating IL-13/STAT6 and INF-γ/p38 pathways. The gene discussed is IL13; the disease is hypersensitivity pneumonitis.